Pilot Study to Investigate the Safety & Feasibility of AntiRetroviral

Status Active, not recruiting

Clinical Trial Summary

The objective of the study is to evaluate the ability of (-)-L-2',3'-dideoxy-3'-thiacytidine (3TC) to engage its intended target, penetrate the central nervous system (CNS), suppress neurodegeneration, and assess safety and tolerability in patients with early stage Alzheimer's disease. This study will provide the initial data on target engagement and Alzheimer's disease-relevant outcomes for future trials.

Clinical Trial Description

This open label study of 3TC will collect initial proof-of-concept data on 3TC target engagement, CNS penetration, efficacy and safety in older adults with early stage Alzheimer's disease. If successful, data will be used to design a larger phase 2 clinical trial. The investigators aim to I) Quantify 3TC target engagement and CNS penetration, II) Determine if 3TC suppresses Alzheimer's disease-relevant outcomes, and III) Assess the safety and tolerability of 3TC in older individuals with early Alzheimer's disease. The study will consist of a screening/baseline period of 30 days pre-treatment, a 24-week open label treatment period, and a follow up visit one month following treatment. Visits to the clinic include a pre-treatment screening visit that includes a comprehensive neuropsychological exam, a tablet-based neuropsychological exam, and a blood draw. For eligible participants, a lumbar puncture will be performed on day one of treatment. Participants will visit the clinic on day one of treatment and at weeks 8, 16, and 24 of treatment to complete medication checks, physical examinations, tablet-based cognitive screening, and blood draw. At week 24 of treatment, patients will undergo a post-treatment comprehensive neuropsychological exam, a lumbar puncture to collect cerebrospinal fluid, and a blood draw. One month after the final dose of medication, participants will return to the clinic for a final safety assessment and disenrollment. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04552795
Study type	Interventional
Source	The University of Texas Health Science Center at San Antonio
Contact
Status	Active, not recruiting
Phase	Phase 1/Phase 2
Start date	February 15, 2021
Completion date	June 2024

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT03625401` - Efficacy and Safety of AD-35 in Treatment of Subjects With Mild to Moderate Alzheimer's Disease	Phase 2
Recruiting	`NCT05983575` - A Pivotal Study of LIPUS-Brain in Patients With Early Alzheimer's Disease	Phase 3
Completed	`NCT05989087` - The Resting-state EEG Gamma Oscillations in Alzheimer's Disease
Recruiting	`NCT06080659` - Network-based biOmarker Discovery of Neurodegenerative Diseases Using Multimodal Connectivity	N/A
Not yet recruiting	`NCT06099587` - MIMA Pilot Study: MIcrostructure of the Medial Temporal Lobe in Early Alzheimer's Disease	N/A
Not yet recruiting	`NCT05604183` - Hyperspectral Retinal Observations for the Cross-sectional Detection of Alzheimer's Disease	N/A
Withdrawn	`NCT03514875` - Effects of Mitochondrial-targeted Antioxidant on Mild Cognitive Impairment (MCI) Patients	N/A
Recruiting	`NCT06203106` - NYSCF Scientific Discovery Biobank
Completed	`NCT03706885` - Efavirenz for Patients With Alzheimer's Disease	Phase 1
Active, not recruiting	`NCT03661034` - Study of Tolerability, Safety and Efficacy of Sensory Stimulation at Multiple Dose Levels to Improve Brain Function (Etude Study)	N/A
Not yet recruiting	`NCT05006599` - SNIFF - 3-Week Aptar CPS Device	Phase 2
Recruiting	`NCT02740634` - Molecular and Structural Imaging in Alzheimer's Disease: A Longitudinal Study	N/A
Active, not recruiting	`NCT03069391` - The Interactive Physical and Cognitive Exercise System	N/A
Recruiting	`NCT04701957` - The Ketogenic Diet for Alzheimer's Disease	N/A
Recruiting	`NCT06268886` - Study to Evaluate the Efficacy, Safety, and Tolerability of an Anti-MTBR Tau Monoclonal Antibody (BMS-986446) in Participants With Early Alzheimer's Disease	Phase 2
Recruiting	`NCT04100889` - A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Alzheimer's Disease
Recruiting	`NCT04656860` - Juice Plus Supplement Clinical Trial	N/A
Recruiting	`NCT05315895` - The Dampness Syndrome of Chinese Medicine Cohort Study
Recruiting	`NCT04916964` - Adapted Home-based Exercise Program "T&E" (Test-and-Exercise) in Persons With Alzheimer's Disease (HOPE Trial)	N/A
Recruiting	`NCT04804618` - Proteomics Study of Mild Cognitive Impairment and Alzheimer's Disease

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Pilot Study to Investigate the Safety and Feasibility of AntiRetroviral Therapy for Alzheimer's Disease — ART-AD

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms